Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 1,587 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 1,587 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $80.95, for a total value of $128,467.65. Following the completion of the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,239,506.40. The trade was a 9.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Price Performance

NASDAQ ORKA traded up $13.04 during trading on Monday, reaching $85.38. The company’s stock had a trading volume of 4,200,226 shares, compared to its average volume of 1,048,601. Oruka Therapeutics, Inc. has a 1-year low of $10.77 and a 1-year high of $91.00. The business has a 50-day moving average price of $65.16 and a 200-day moving average price of $45.89.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, equities analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on ORKA shares. UBS Group increased their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Wedbush set a $165.00 price target on Oruka Therapeutics in a research report on Monday, April 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, April 30th. Finally, BTIG Research reissued a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday, May 14th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $131.30.

Institutional Trading of Oruka Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its stake in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics during the 4th quarter worth $37,000. PNC Financial Services Group Inc. bought a new stake in Oruka Therapeutics during the third quarter valued at about $39,000. Caitong International Asset Management Co. Ltd bought a new stake in Oruka Therapeutics during the fourth quarter valued at about $67,000. Finally, Russell Investments Group Ltd. bought a new stake in Oruka Therapeutics during the third quarter valued at about $43,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.